Zobrazeno 1 - 10
of 312
pro vyhledávání: '"Komal Jhaveri"'
Autor:
Nicholas Mai, Carlos H. dos Anjos, Pedram Razavi, Anton Safonov, Sujata Patil, Yuan Chen, Joshua Z. Drago, Shanu Modi, Jacqueline F. Bromberg, Chau T. Dang, Dazhi Liu, Larry Norton, Mark Robson, Sarat Chandarlapaty, Komal Jhaveri
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-9 (2024)
Abstract After disease progression on endocrine therapy (ET) plus a CDK4/6 inhibitor, there is no standardized sequence for subsequent treatment lines for estrogen receptor positive (ER+) metastatic breast cancer (MBC). CDK4/6i retrial as a treatment
Externí odkaz:
https://doaj.org/article/88f817264c2f476b8cdad0ce4fa3f038
Autor:
Komal Jhaveri, Joyce O’Shaughnessy, Peter A. Fasching, Sara M. Tolaney, Denise A. Yardley, Vikash Kumar Sharma, Chandroday Biswas, Astrid Thuerigen, Purnima Pathak, Hope S. Rugo
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Current standard-of-care first-line treatment of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer (ABC) is cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + end
Externí odkaz:
https://doaj.org/article/f9fa04a73b63440b97588ebecf3c53a7
Autor:
James J. Harding, Sarina A. Piha-Paul, Ronak H. Shah, Jessica J. Murphy, James M. Cleary, Geoffrey I. Shapiro, David I. Quinn, Irene Braña, Victor Moreno, Mitesh Borad, Sherene Loi, Iben Spanggaard, Haeseong Park, James M. Ford, Mónica Arnedos, Salomon M. Stemmer, Christelle de la Fouchardiere, Christos Fountzilas, Jie Zhang, Daniel DiPrimeo, Casey Savin, S. Duygu Selcuklu, Michael F. Berger, Lisa D. Eli, Funda Meric-Bernstam, Komal Jhaveri, David B. Solit, Ghassan K. Abou-Alfa
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-12 (2023)
In biliary tract cancer HER2 alterations correlate with poor prognosis. Here, the authors present the results of a phase II clinical trial reporting the efficacy and safety of the tyrosine kinase inhibitor neratinib in patients with HER2-mutation pos
Externí odkaz:
https://doaj.org/article/6b0c6dc798b14d37bd9664bd41aec7e1
Autor:
Andi K. Cani, Emily M. Dolce, Elizabeth P. Darga, Kevin Hu, Chia‐Jen Liu, Jackie Pierce, Kieran Bradbury, Elaine Kilgour, Kimberly Aung, Gaia Schiavon, Danielle Carroll, T. Hedley Carr, Teresa Klinowska, Justin Lindemann, Gayle Marshall, Vicky Rowlands, Elizabeth A. Harrington, J. Carl Barrett, Nitharsan Sathiyayogan, Christopher Morrow, Valeria Sero, Anne C. Armstrong, Richard Baird, Erika Hamilton, Seock‐Ah Im, Komal Jhaveri, Manish R. Patel, Caroline Dive, Scott A. Tomlins, Aaron M. Udager, Daniel F. Hayes, Costanza Paoletti
Publikováno v:
Molecular Oncology, Vol 16, Iss 10, Pp 1969-1985 (2022)
Nearly all estrogen receptor (ER)‐positive (POS) metastatic breast cancers become refractory to endocrine (ET) and other therapies, leading to lethal disease presumably due to evolving genomic alterations. Timely monitoring of the molecular events
Externí odkaz:
https://doaj.org/article/3982ed92674c47fd83894acff6f5a9d3
Autor:
Dazhi Liu, Michael A. Weintraub, Christine Garcia, Marcus D. Goncalves, Ann Elizabeth Sisk, Alissa Casas, James J. Harding, Stephen Harnicar, Alexander Drilon, Komal Jhaveri, James H. Flory
Publikováno v:
Cancer Medicine, Vol 11, Iss 8, Pp 1796-1804 (2022)
Abstract Purpose The phosphoinositide 3‐kinase (PI3K)/protein kinase B (AKT) pathway controls insulin sensitivity and glucose metabolism. Hyperglycemia is one of the most common on‐target adverse effects (AEs) of PI3K/AKT inhibitors. As several P
Externí odkaz:
https://doaj.org/article/6261ca0f91da4aafad9291fcc66547c9
Autor:
Hope S. Rugo, Victoria Harmer, Joyce O’Shaughnessy, Komal Jhaveri, Sara M. Tolaney, Fatima Cardoso, Aditya Bardia, Vikalp Kumar Maheshwari, Sandeep Tripathi, Sina Haftchenary, Purnima Pathak, Peter A. Fasching
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: A cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + endocrine therapy is recommended as first-line treatment for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer (ABC). Quali
Externí odkaz:
https://doaj.org/article/a59fc0d94e7e47a49b737be7dc5282f2
Autor:
Lillian M. Smyth, Gerald Batist, Funda Meric-Bernstam, Peter Kabos, Iben Spanggaard, Ana Lluch, Komal Jhaveri, Andrea Varga, Andrea Wong, Alison M. Schram, Helen Ambrose, T. Hedley Carr, Elza C. de Bruin, Carolina Salinas-Souza, Andrew Foxley, Joana Hauser, Justin P. O. Lindemann, Rhiannon Maudsley, Robert McEwen, Michele Moschetta, Myria Nikolaou, Gaia Schiavon, Pedram Razavi, Udai Banerji, José Baselga, David M. Hyman, Sarat Chandarlapaty
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-7 (2021)
Abstract Five to ten percent of ER+ metastatic breast cancer (MBC) tumors harbor somatic PTEN mutations. Loss of function of this tumor-suppressor gene defines a highly aggressive, treatment-refractory disease for which new therapies are urgently nee
Externí odkaz:
https://doaj.org/article/97cb292e26054c75a968bad21fc37c9b
Autor:
Brendan John Guercio, Gopa Iyer, Wajih Zaheer Kidwai, Mario E. Lacouture, Soleen Ghafoor, Anthony M. Rossi, David N. Assis, Ying-Bei Chen, Klaus J. Busam, Yelena Y. Janjigian, Komal Jhaveri, Darren R. Feldman, Anne Capozzi, Vanessa Figueroa, Dean F. Bajorin, Jonathan E. Rosenberg, Travis J. Hollmann, Samuel A. Funt
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 1, Pp 430-438 (2021)
Metastatic primary cutaneous extramammary Paget disease (EMPD) is a rare clinical entity with a 5-year survival
Externí odkaz:
https://doaj.org/article/d76cb10bfe2348a4802b4d6e377656f7
Autor:
Sara M. Tolaney, Muralidhar Beeram, J. Thaddeus Beck, Alison Conlin, E. Claire Dees, Shannon L. Puhalla, Brent N. Rexer, Howard A. Burris, Komal Jhaveri, Teresa Helsten, Carlos Becerra, Kevin Kalinsky, Kathleen N. Moore, Allison M. Manuel, Andrew Lithio, Gregory L. Price, Sonya C. Chapman, Lacey M. Litchfield, Matthew P. Goetz
Publikováno v:
Frontiers in Oncology, Vol 11 (2022)
BackgroundCyclin-dependent kinases (CDK) 4 and 6 regulate G1 to S cell cycle progression and are often altered in cancers. Abemaciclib is a selective inhibitor of CDK4 and CDK6 approved for administration on a continuous dosing schedule as monotherap
Externí odkaz:
https://doaj.org/article/0ebf489cd41e4cb59d2713c43b686f6f
Autor:
Hope Rugo, Aditya Bardia, Frederik Marmé, Javier Cortés, Peter Schmid, Delphine Loirat, Olivier Trédan, Eva Ciruelos, Florence Dalenc, Patricia Gómez Pardo, Komal Jhaveri, Monica Motwani, Oh Kyu Yoon, Hao Wang, Wendy Verret, Sara Tolaney
Publikováno v:
Cancer Research. 83:GS1-11
Background: HR+/HER2– mBC, the most common subset of breast cancer, is treated with sequential endocrine therapy + targeted agents followed by sequential single-agent chemotherapy (CT), with increasingly shorter benefit duration with each subsequen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0456df6c4f83cb82228474fa80e88ba5
https://doi.org/10.1158/1538-7445.sabcs22-gs1-11
https://doi.org/10.1158/1538-7445.sabcs22-gs1-11